Pharmacokinetics of bisphosphonates in rabbits

被引:6
|
作者
Luurila, S [1 ]
Kautiainen, S [1 ]
Ylitalo, P [1 ]
Ylitalo, R [1 ]
机构
[1] Univ Tampere, Dept Pharmacol Sci, FIN-33101 Tampere, Finland
来源
PHARMACOLOGY & TOXICOLOGY | 1999年 / 84卷 / 01期
关键词
D O I
10.1111/j.1600-0773.1999.tb02106.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clodronate, pamidronate and etidronate are commonly used bisphosphonates. which accumulate extensively in arteries and some other tissues. We compared their pharmacokinetics in rabbits with those of tiludronate. the drug newly introduced to clinical use. The C-14-labelled drugs were given intravenously and plasma drug levels were monitored for up to 24 hr. The dose-related plasma concentrations of tiludronate and etidronate were clearly higher and decreased more slowly than those of clodronate and pamidronate (P<0.001). Already at 5 min., the concentrations of tiludronate and etidronate were higher than those of clodronate and pamidronate (P=0.016). At 24 hr, plasma concentration of tiludronate was 12+/-6.6%. of etidronate 18+/-2.5%, of clodronate 0.8+/-0.2%, and of pamidronate 1.5+/-0.44% of the dose per body weight. With the same dose (25 mg/kg), absolute AUC(0-24hr) for tiludronate and etidronate was 9-11 times larger than for clodronate. AUC(0-24hr) for pamidronate (2.5 mg/kg) was 11% of that for clodronate. Plasma clearance of tiludronate and etidronate was 9-15 times slower than that of clodronate and pamidronate. At 24 hr, the mean tissue-to-plasma ratio of tiludronate for aorta was 1.2-1.6. For bone, spleen, liver and kidneys the ratio varied from 5.4 to 52.6. The results suggest that 1) tiludronate and etidronate are removed from plasma much slower than clodronate and pamidronate, and 2) the potential of tiludronate to concentrate in arteries and bone is generally smaller than previously found with the other bisphosphonates.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 50 条
  • [21] Ocular pharmacokinetics of verapamil in rabbits
    A. Ettl
    U. Hofmann
    Albert Daxer
    Hermann Dietrich
    Eduard Schmid
    Michel Eichelbaum
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357 : 331 - 335
  • [22] PHARMACOKINETICS OF MINOCYCLINE AND VANCOMYCIN IN RABBITS
    NICOLAU, DP
    FREEMAN, CD
    NIGHTINGALE, CH
    QUINTILIANI, R
    LABORATORY ANIMAL SCIENCE, 1993, 43 (03): : 222 - 225
  • [23] PHARMACOKINETICS OF IOPROMIDE LIPOSOMES IN RABBITS
    SCHUHMANNGIAMPIERI, G
    LEIKE, J
    SACHSE, A
    KRAUSE, W
    PHARMACEUTICAL RESEARCH, 1995, 12 (07) : 1065 - 1071
  • [24] PHARMACOKINETICS OF OXYTETRACYCLINE HYDROCHLORIDE IN RABBITS
    MCELROY, DE
    RAVIS, WR
    CLARK, CH
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 1987, 48 (08) : 1261 - 1263
  • [25] Ocular pharmacokinetics of verapamil in rabbits
    Ettl, A
    Hofmann, U
    Daxer, A
    Dietrich, H
    Schmid, E
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (03) : 331 - 335
  • [26] PHARMACOKINETICS OF DIBEKACIN IN RABBITS AND DOGS
    KOMIYA, I
    MURATA, S
    UMEMURA, K
    TOMONO, N
    KIKAI, S
    FUJITA, M
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1981, 4 (05): : 362 - 373
  • [27] PHARMACOKINETICS OF HARRINGTONINE LIPOSOMES IN RABBITS
    WU, HL
    WENG, GY
    WU, ZH
    LU, YC
    ACTA PHARMACOLOGICA SINICA, 1994, 15 (01): : 84 - 86
  • [28] SULACILLIN PHARMACOKINETICS IN EXPERIMENTAL RABBITS
    BEDNOVA, VN
    DMITRIYEV, GA
    VASILYEV, MM
    NAVOLOTSKAYA, TI
    MIRZAYEV, MP
    VESTNIK DERMATOLOGII I VENEROLOGII, 1994, (06) : 15 - 17
  • [29] OCULAR PHARMACOKINETICS OF THIAMPHENICOL IN RABBITS
    ALDANA, I
    FOS, D
    PENAS, EG
    GAZZANIGA, A
    GIANESELLO, V
    MONTI, NC
    FIGINI, PG
    ZATO, MA
    BRUSEGHINI, L
    ESTERAS, A
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1992, 42-2 (10): : 1236 - 1239
  • [30] PHARMACOKINETICS OF BUTORPHANOL TARTRATE IN RABBITS
    PORTNOY, LG
    HUSTEAD, DR
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 1992, 53 (04) : 541 - 543